Physician profile
Simon Mcclure
NPI 1386677813
$21,197.24
in general payments reported to CMS, 2019-2025
32 companies · $3,818 in 2025
The $3,818 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,778 · 2020: $1,485 · 2021: $2,330 · 2022: $3,665 · 2023: $4,392 · 2024: $2,728 · 2025: $3,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,827.20 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,283.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $2,034.94 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,935.46 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,760.97 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,548.86 | 2021-2025 | |
| Alkermes, INC. | $1,400.05 | 2019-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $1,293.00 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $1,152.83 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,067.91 | 2020-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $996.89 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $923.00 | 2019-2025 | Spravato |
| Corium, LLC | $739.21 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $722.21 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $644.48 | 2019-2025 | Rexulti, Abilify Maintena |
| Neos Therapeutics, Lp | $407.32 | 2019-2023 | Adzenys Xr-Odt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $374.02 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Allergan, INC. | $362.97 | 2019-2020 | |
| Bausch Health US, LLC | $340.36 | 2019-2025 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $315.43 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $223.92 | 2019-2024 | |
| Eisai INC. | $143.92 | 2020-2022 | |
| Tris Pharma INC | $98.57 | 2022-2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $86.49 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $84.94 | 2019-2021 | |
| Noven Therapeutics, LLC | $55.55 | 2020-2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $49.86 | 2020-2021 | |
| Shire North American Group INC | $43.62 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.95 | 2025 | Rejoyn |
| Adlon Therapeutics L.P. | $26.10 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $20.05 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.63 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.